Key takeaways

  • British American Tobacco features in recent broker views as flagged by Sharecast for the week ending 1 June 2026.
  • BATS shares closed near $61.72 on the NYSE on 29 May 2026; Market Capitalisation is approximately £93.55bn.
  • The 2026 First Half Pre-Close Trading Update is scheduled for 2 June 2026 at 07:00 BST.
  • Defensive stock rotation has supported tobacco, utilities and consumer staples in the FTSE 100 throughout the first half of 2026.
  • New Categories — vapour, heated tobacco and modern oral — remain the principal long-term debate among Brokers.
  • Risks include US regulatory action, menthol policy uncertainty and persistent ESG-related institutional avoidance.

Introduction

British American Tobacco plc, the FTSE 100 multinational best known by its London ticker BATS, has reappeared on UK broker recommendation lists as analysts revisit their assumptions ahead of a key trading update. The company is included on the Sharecast Broker Views — Recent Recommendations list for 26 May to 1 June 2026. As with all entries on that list, Sharecast publishes the company and date but not the broker firm, rating or target — so we focus here on context rather than on any specific call.

The timing is meaningful. BATS is due to publish its 2026 First Half Pre-Close Trading Update on Tuesday 2 June 2026 at 07:00 BST, with a conference call hosted by chief executive Tadeu Marroco at 08:30 BST. Analysts routinely fine-tune their models in the days before such a release, which would explain the renewed broker activity. The wider market backdrop is also supportive: defensive UK stocks have led the FTSE 100 in the first half of 2026 as investors hunt for resilient cash flows in a still-choppy macro environment.

BATS itself has rallied around 9% since the start of 2026 in dollar terms, with the shares closing near $61.72 on the NYSE on 29 May 2026 and the London-listed Equity trading consistently close to recent highs. Market capitalisation stands at roughly £93.55bn, anchoring BATS firmly among the FTSE 100's largest Dividend-paying defensives. Investors are watching whether the upcoming trading update can sustain that momentum or whether brokers begin to lock in the year's gains.

Company background

British American Tobacco is one of the world's largest tobacco and nicotine companies, with operations in more than 175 markets and a portfolio that combines combustible cigarette brands such as Dunhill, Lucky Strike, Pall Mall and Rothmans with a rapidly scaling New Categories Business spanning vapour (Vuse), heated tobacco (glo) and modern oral nicotine (Velo). The company is headquartered in London, dual-listed in London and on the New York Stock Exchange, and has been a constituent of the FTSE 100 since the index's inception.

The group employs more than 50,000 people globally and generates very large operating cash flows from a relatively narrow group of high-Margin product categories. That cash-generative profile has historically underpinned a generous dividend policy, with BATS consistently ranking among the largest dividend payers in the entire UK equity market.

Strategically, the group has spent the past decade pivoting Capital and management attention toward New Categories. While combustibles still account for the majority of Revenue and profit, the long-term narrative — and a substantial proportion of the bull case — increasingly rests on the trajectory of vapour, heated tobacco and modern oral, all of which carry different risk and regulatory profiles to the traditional cigarette business.

Why the stock is in broker focus

Multiple drivers explain why brokers are revisiting BATS now. The first is the looming pre-close trading update on 2 June. Analysts typically use the days before pre-close statements to refresh divisional assumptions on cigarette Volume declines, New Category growth rates, currency translation and capital returns. A pre-close statement that confirms or upgrades full-year guidance can move the share price meaningfully, especially in a low-Volatility defensive name.

The second driver is the broader defensive rotation. Defensive names including utilities, consumer staples, healthcare and telecoms benefit from lower discount rates on stable cash flows in the current environment. The FTSE 100's defensive assortment — pharmaceuticals, utilities, tobacco and consumer goods — has performed strongly into 2026 as investors prioritise visible income streams. BATS, with its high single-digit Yield/">Dividend Yield and very predictable cash conversion, is a natural beneficiary.

Third, New Category dynamics. Investors are watching closely for evidence that combined Vuse, glo and Velo revenue continues to scale toward profitability targets management has previously articulated. Markets such as the United States (Vuse), Japan (glo) and Scandinavia/US (Velo) are particularly important to that trajectory and are frequently called out in broker notes.

Finally, capital allocation is back in focus. BATS has continued a steady cadence of share repurchases alongside its dividend, and any incremental commentary on buyback pacing, Leverage targets or M&A appetite tends to influence broker valuation work.

Recent share price and market performance

BATS has delivered a strong year-to-date performance. The shares closed at $61.72 on the NYSE on 29 May 2026, putting the dollar-denominated equity up roughly 9% since the start of 2026. The London-listed line has tracked that performance closely, with the FTSE 100 quote trading near 2026 highs. Market capitalisation now stands at approximately £93.55bn, comfortably placing BATS among the largest twenty stocks in the FTSE 100.

Over a longer horizon, BATS has finally clawed back much of the underperformance that dogged the stock through 2018 to 2023, when ESG-led divestment, regulatory anxiety and slow visible progress on New Categories weighed on sentiment. The recovery has been earned through consistent delivery — modest organic revenue growth, robust cash conversion, disciplined capital allocation and progressive — though slower — dividend growth.

Volumes on the London line have been consistent with growing institutional engagement rather than a speculative spike. Income-focused mandates have been steady buyers, and several long-only managers who previously underweighted the stock have moved back to benchmark weight. Hedge fund involvement remains modest by comparison with more cyclical FTSE 100 names.

Volatility metrics remain notably contained. Options markets are not pricing in dramatic near-term moves, though as is always the case, a meaningful surprise in the 2 June pre-close statement could compress or expand realised volatility quickly.

Sector outlook

The global tobacco and nicotine sector is in the middle of a structural transition. Combustible cigarette volumes are in steady decline across most developed markets, while next-generation products — vapour, heated tobacco and modern oral nicotine — are growing at robust rates. Pricing power on combustibles, supported by industry concentration and inelastic Demand among existing smokers, continues to offset most of the volume erosion in revenue terms.

Defensive characteristics remain a key part of the bull narrative for the sector. Tobacco companies like British American Tobacco and Imperial Brands are widely viewed as in constant demand regardless of macroeconomic concerns, with the ability to increase prices to match Inflation. This profile makes the group particularly attractive in periods of market stress or rotation away from cyclicality.

Regulatory Risk, however, is genuinely sector-wide. The US Food and Drug Administration's posture on menthol cigarettes, flavoured vapour products and nicotine yield standards has the capacity to reshape entire revenue lines. European authorities, the UK Government and various Asian regulators each have their own evolving policy frameworks. Brokers spend a disproportionate amount of time on regulatory mapping when modelling the sector.

Competitive dynamics among the global majors — Philip Morris International, BAT, Altria, Japan Tobacco International and Imperial Brands — are intensifying around New Categories. Each player has placed bets on different product formats and geographies. BATS's portfolio breadth across vapour, heated tobacco and modern oral is broader than most peers, but the trade-off is greater complexity and higher near-term Investment intensity.

Broker sentiment and valuation debate

Broker sentiment on BATS has improved meaningfully from the cautious tone that prevailed in 2022-2023. The valuation case rests on several pillars. The shares trade on a forward price-to-Earnings multiple that remains a discount to the broader FTSE 100 and a deep discount to consumer staples peers. Dividend yield, even after the year-to-date rally, remains comfortably above gilt yields and supports the income-oriented investment case.

The bull case can be summarised in four points. First, combustible pricing continues to offset volume declines. Second, New Categories scale toward profitability with strong consumer traction in vapour and heated tobacco. Third, free Cash Flow conversion remains exceptional and supports continued Buybacks and dividend growth. Fourth, ongoing capital returns offer a credible mechanism for Shareholder value creation even in the absence of multiple expansion.

The bear case focuses on regulatory Tail risk, particularly in the United States; the long-term decline of combustibles; ESG-driven institutional underweights that limit the marginal buyer base; and the possibility that New Category profitability arrives more slowly or at lower margins than current consensus assumes. Litigation risk, while quieter than in previous decades, has not disappeared entirely.

Brokers are also watching foreign exchange. As a US dollar earner with a significant emerging market footprint, BATS's reported numbers are sensitive to the trajectory of sterling against the dollar and against a basket of EM currencies. The 2026 sterling environment has been relatively benign for translation, but this can shift quickly.

Risks investors are watching

US regulatory risk tops most risk registers. Any meaningful tightening of menthol policy, an aggressive nicotine yield standard or material restrictions on flavoured vapour could affect both combustible and New Category profit pools. While BATS has invested substantially in compliance and product development, the policy environment in Washington can shift rapidly.

Litigation risk, though comparatively quiet, remains a structural feature of the industry. Vapour and heated tobacco products have not yet generated the volume of legal challenge that historically affected combustibles, but vigilance is required as those product categories mature.

ESG-related institutional avoidance continues to limit BATS's marginal buyer base. A growing share of European pension and sovereign Wealth capital is restricted from holding tobacco names. While the marginal buyer is currently engaged enough to allow the shares to rally, this structural feature means BATS can trade at a persistent discount to its purer staples peers.

Macroeconomic Factors, while less impactful for BATS than for many cyclicals, still matter. Down-trading in lower-income consumer pockets, currency volatility in EM markets and any meaningful surge in inflation that outpaces pricing power are all variables analysts continue to monitor.

Potential catalysts

The 2 June 2026 pre-close trading update is the most immediate potential catalyst. Investors will pay close attention to commentary on volume trends, pricing achievability, New Categories revenue growth and any update on full-year guidance. Tone from chief executive Tadeu Marroco on the accompanying conference call will be carefully parsed.

Half-year results, scheduled for late July 2026, will be the next major data point. Beyond the divisional numbers, investors will look for incremental detail on New Category profitability trajectories, capital allocation and any commentary on the pace of share repurchases.

Regulatory developments — notably any US Food and Drug Administration product authorisations, label rulings or rule-making updates — represent both potential upside and downside catalysts. Approvals for additional Vuse SKUs or favourable rulings on heated tobacco can move estimates meaningfully.

Finally, broader market dynamics matter. Should defensive rotation continue and should gilt yields drift lower into late 2026, the relative attractiveness of high dividend yielders like BATS would be enhanced further. Conversely, a sharp yield back-up could trim some of the year-to-date defensive premium.

What happens next

The immediate focus is the 2 June trading update. A reassuring statement that confirms full-year guidance and provides incremental colour on New Categories would likely be enough to sustain the year-to-date share price momentum, particularly given the supportive defensive backdrop. Brokers are likely to refine rather than overhaul their published views in the wake of such a release.

A more transformational catalyst would be a positive surprise on New Category profitability or an upgraded full-year outlook. Either could prompt broker upgrades and a more pronounced re-rating. Conversely, any indication of slower-than-expected progress in vapour or heated tobacco profitability, or any adverse regulatory signal, could see brokers turn more cautious.

Beyond June, the market will look for evidence that BATS's strategic pivot is delivering durable value. The half-year results in late July and the full-year results early in 2027 will be the next milestones. Investors are watching to see whether the current rally is consolidated into a sustained re-rating of the equity.

Conclusion

British American Tobacco's reappearance on broker recommendation lists in late May 2026 captures the company's improved standing in the eyes of the UK financial community. With the shares up around 9% year-to-date, a critical trading update imminent and defensive rotation supporting valuations across the FTSE 100, BATS is enjoying a moment of renewed attention.

Whether the next phase of broker activity skews more positive or more cautious will depend on the substance of the 2 June 2026 pre-close trading update and on subsequent results. The underlying story — cash-generative combustibles, scaling New Categories, robust capital returns — is intact. The valuation, while undemanding versus peers, has firmed alongside the share price. For now, BATS remains a watchlist name for income-focused UK investors and for any portfolio seeking defensive ballast in the current FTSE 100 environment.